Low-dose Computed Tomography Screening: The (Other) Lung Cancer Revolution

The advent of immune checkpoint inhibitors for the treatment of metastatic non-small cell lung cancers has been a bright spot in the otherwise bleak landscape of the UK's deadliest cancer. In a disease where two-thirds of those who present with a new diagnosis will be dead within a year, and survival outcomes have changed little in the last four decades [[1]Lung cancer statistics. Cancer Research...